Prospects for nutritional control of hypertension.
Sodium restriction is not the only nutritional measure likely to prove valuable in the treatment and prevention of hypertension. The hypotensive effects of central adrenergic stimulation can be promoted by supplementary tyrosine, insulin potentiation (as with GTF), and (possibly) high-dose pyridoxine. Insulin potentiators (GTF) and prostaglandin precursors (essential fatty acids) should have direct relaxant effects on vascular muscle. A high potassium, low sodium diet, coenzyme Q, and prevention of cadmium toxicity (as with dietary selenium) may act to offset renally-mediated pressor influences. Functional combinations of these measures might prove to be substantially effective, in which case they would offer considerable advantages over potentially toxic drug therapies.
D000596:Amino Acids / Q000627:therapeutic use; D000818:Animals; D002857:Chromium / Q000627:therapeutic use; D004039:Diet, Sodium-Restricted; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D004044:Dietary Proteins / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006168:Guinea Pigs; D006801:Humans; D006973:Hypertension / Q000178:diet therapy*; D009539:Nicotinic Acids / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D011736:Pyridoxine / Q000627:therapeutic use; D051381:Rats; D014443:Tyrosine / Q000627:therapeutic use; D014451:Ubiquinone / Q000627:therapeutic use
D000596:Amino Acids; D004040:Dietary Carbohydrates; D004044:Dietary Proteins; D009539:Nicotinic Acids; D009942:Organometallic Compounds; C015240:glucose tolerance factor; D002857:Chromium; D014451:Ubiquinone; D014443:Tyrosine; D011736:Pyridoxine; D011188:Potassium